S.Korea approves phase II human trial for Green Cross's coronavirus treatment drug

GC Biopharma

20/08/2020 01:40

SEOUL, Aug 20 (Reuters) - South Korea's Green Cross Corp
 006280.KS  has received regulatory approval for phase II human
clinical trials of its experimental coronavirus plasma treatment
drug, the Ministry of Food and Drug Safety said on Thursday. 
    The trials will test the safety and efficacy of the drug in
60 severe patients with underlying conditions like pneumonia,
Green Cross said. 
    Green Cross was allowed to skip phase I trials. Its therapy
is the country's first to enter phase II for COVID-19 plasma
treatment.  urn:newsml:reuters.com:*:nL3N2F01TW 

    

        

 (Reporting by Sangmi Cha; Editing by Tom Hogue)
 ((Sangmi.Cha@thomsonreuters.com; +82 2 3704 5646; Reuters
Messaging: sangmi.cha.thomsonreuters.com@reuters.net))